Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Other Operating Expenses (2022 - 2025)

Arcturus Therapeutics Holdings' Other Operating Expenses history spans 3 years, with the latest figure at $128.0 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 36.98% year-over-year to $128.0 million; the TTM value through Dec 2025 reached $91.3 million, up 62.35%, while the annual FY2022 figure was -$191.0 million, N/A changed from the prior year.
  • Other Operating Expenses reached $128.0 million in Q4 2025 per ARCT's latest filing, up from -$36.7 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $203.2 million in Q4 2024 to a low of -$191.0 million in Q4 2022.
  • Average Other Operating Expenses over 3 years is -$7.2 million, with a median of -$54.4 million recorded in 2024.
  • The largest YoY upside for Other Operating Expenses was 36.98% in 2025 against a maximum downside of 36.98% in 2025.
  • A 3-year view of Other Operating Expenses shows it stood at -$191.0 million in 2022, then skyrocketed by 206.37% to $203.2 million in 2024, then plummeted by 36.98% to $128.0 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Other Operating Expenses are $128.0 million (Q4 2025), -$36.7 million (Q3 2025), and $203.2 million (Q4 2024).